Focused On-demand Library for WD repeat-containing protein 11

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9BZH6

UPID:

WDR11_HUMAN

Alternative names:

Bromodomain and WD repeat-containing protein 2; WD repeat-containing protein 15

Alternative UPACC:

Q9BZH6; Q5VWA1; Q9P2J6

Background:

WD repeat-containing protein 11, also known as Bromodomain and WD repeat-containing protein 2 or WD repeat-containing protein 15, plays a crucial role in the Hedgehog signaling pathway, vital for normal ciliogenesis. It is instrumental in the proteolytic processing of GLI3 and works alongside EMX1 to induce gene expression crucial for gonadotropin-releasing hormone production.

Therapeutic significance:

This protein is linked to Hypogonadotropic hypogonadism 14 with or without anosmia and Intellectual developmental disorder, autosomal recessive 78, diseases caused by gene variants. Understanding its role could lead to novel therapeutic strategies for these conditions.